A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer
Crossref DOI link: https://doi.org/10.1007/s00262-015-1781-6
Published Online: 2016-01-04
Published Print: 2016-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Noguchi, Masanori
Moriya, Fukuko
Koga, Noriko
Matsueda, Satoko
Sasada, Tetsuro
Yamada, Akira
Kakuma, Tatsuyuki
Itoh, Kyogo
Text and Data Mining valid from 2016-01-04